157 related articles for article (PubMed ID: 31719064)
1. Hepatitis C Virus Infection and the Temporal Trends in the Risk of Liver Cancer: A National Register-Based Cohort Study in Sweden.
Batyrbekova N; Aleman S; Lybeck C; Montgomery S; Duberg AS
Cancer Epidemiol Biomarkers Prev; 2020 Jan; 29(1):63-70. PubMed ID: 31719064
[TBL] [Abstract][Full Text] [Related]
2. Direct-acting antiviral treatment for hepatitis C virus infection and risk of incident liver cancer: a retrospective cohort study.
Singer AW; Reddy KR; Telep LE; Osinusi AO; Brainard DM; Buti M; Chokkalingam AP
Aliment Pharmacol Ther; 2018 May; 47(9):1278-1287. PubMed ID: 29516535
[TBL] [Abstract][Full Text] [Related]
3. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
Duberg AS; Blach S; Falconer K; Kåberg M; Razavi H; Aleman S
Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
[TBL] [Abstract][Full Text] [Related]
4. Declining hepatitis C virus-related liver disease burden in the direct-acting antiviral therapy era in New South Wales, Australia.
Alavi M; Law MG; Valerio H; Grebely J; Amin J; Hajarizadeh B; Selvey C; George J; Dore GJ
J Hepatol; 2019 Aug; 71(2):281-288. PubMed ID: 31078544
[TBL] [Abstract][Full Text] [Related]
5. Sustained virologic response to direct-acting antiviral agents predicts better outcomes in hepatitis C virus-infected patients: A retrospective study.
Colussi G; Donnini D; Brizzi RF; Maier S; Valenti L; Catena C; Cavarape A; Sechi LA; Soardo G
World J Gastroenterol; 2019 Oct; 25(40):6094-6106. PubMed ID: 31686765
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma and other primary liver cancers in hepatitis C patients in Sweden - a low endemic country.
Strauss R; Törner A; Duberg AS; Hultcrantz R; Ekdahl K
J Viral Hepat; 2008 Jul; 15(7):531-7. PubMed ID: 18397224
[TBL] [Abstract][Full Text] [Related]
7. Extrahepatic cancers are the leading cause of death in patients achieving hepatitis B virus control or hepatitis C virus eradication.
Allaire M; Nahon P; Layese R; Bourcier V; Cagnot C; Marcellin P; Guyader D; Pol S; Larrey D; De Lédinghen V; Ouzan D; Zoulim F; Roulot D; Tran A; Bronowicki JP; Zarski JP; Riachi G; Calès P; Péron JM; Alric L; Bourlière M; Mathurin P; Blanc JF; Abergel A; Serfaty L; Mallat A; Grangé JD; Attali P; Bacq Y; Wartelle C; Dao T; Thabut D; Pilette C; Silvain C; Christidis C; Nguyen-Khac E; Bernard-Chabert B; Zucman D; DI Martino V; Sutton A; Letouzé E; Audureau E; Roudot-Thoraval F;
Hepatology; 2018 Oct; 68(4):1245-1259. PubMed ID: 29663511
[TBL] [Abstract][Full Text] [Related]
8. Interferon-free therapy of chronic hepatitis C with direct-acting antivirals does not change the short-term risk for de novo hepatocellular carcinoma in patients with liver cirrhosis.
Mettke F; Schlevogt B; Deterding K; Wranke A; Smith A; Port K; Manns MP; Vogel A; Cornberg M; Wedemeyer H
Aliment Pharmacol Ther; 2018 Feb; 47(4):516-525. PubMed ID: 29205405
[TBL] [Abstract][Full Text] [Related]
9. Factors Associated With Increased Risk of De Novo or Recurrent Hepatocellular Carcinoma in Patients With Cirrhosis Treated With Direct-Acting Antivirals for HCV Infection.
Degasperi E; D'Ambrosio R; Iavarone M; Sangiovanni A; Aghemo A; Soffredini R; Borghi M; Lunghi G; Colombo M; Lampertico P
Clin Gastroenterol Hepatol; 2019 May; 17(6):1183-1191.e7. PubMed ID: 30613002
[TBL] [Abstract][Full Text] [Related]
10. The impact of HCV eradication by direct-acting antivirals on the transition of precancerous hepatic nodules to HCC: A prospective observational study.
Toyoda H; Kumada T; Tada T; Mizuno K; Sone Y; Akita T; Tanaka J; Johnson PJ
Liver Int; 2019 Mar; 39(3):448-454. PubMed ID: 30312003
[TBL] [Abstract][Full Text] [Related]
11. Prevalence of chronic hepatitis C virus infection among childhood cancer survivors in Stockholm, Sweden.
Psaros Einberg A; Ekman AT; Söderhäll S; Millbourn C; Lindahl K; Harila-Saari A; Fischler B
Acta Oncol; 2019 Jul; 58(7):997-1002. PubMed ID: 30761933
[No Abstract] [Full Text] [Related]
12. Cancer in People with and without Hepatitis C Virus Infection: Comparison of Risk Before and After Introduction of Direct-Acting Antivirals.
Lam JO; Hurley LB; Lai JB; Saxena V; Seo S; Chamberland S; Quesenberry CP; Champsi JH; Ready J; Chiao EY; Marcus JL; Silverberg MJ
Cancer Epidemiol Biomarkers Prev; 2021 Dec; 30(12):2188-2196. PubMed ID: 34583968
[TBL] [Abstract][Full Text] [Related]
13. Impact of hepatitis C virus treatment on the risk of non-hepatic cancers among hepatitis C virus-infected patients in the US.
Wang W; Lo Re V; Guo Y; Xiao H; Brown J; Park H
Aliment Pharmacol Ther; 2020 Nov; 52(10):1592-1602. PubMed ID: 32931606
[TBL] [Abstract][Full Text] [Related]
14. Viral eradication reduces all-cause mortality in patients with chronic hepatitis C virus infection: a propensity score analysis.
Tada T; Kumada T; Toyoda H; Kiriyama S; Tanikawa M; Hisanaga Y; Kanamori A; Kitabatake S; Yama T; Tanaka J
Liver Int; 2016 Jun; 36(6):817-26. PubMed ID: 26787002
[TBL] [Abstract][Full Text] [Related]
15. Incidence of hospitalization for infection among patients with hepatitis B or C virus infection without cirrhosis in Taiwan: A cohort study.
Lee YC; Wang JL; Dong YH; Chen HC; Wu LC; Chang CH
PLoS Med; 2019 Sep; 16(9):e1002894. PubMed ID: 31518344
[TBL] [Abstract][Full Text] [Related]
16. Direct-acting antivirals and hepatocellular carcinoma in chronic hepatitis C: A few lights and many shadows.
Guarino M; Sessa A; Cossiga V; Morando F; Caporaso N; Morisco F;
World J Gastroenterol; 2018 Jun; 24(24):2582-2595. PubMed ID: 29962815
[TBL] [Abstract][Full Text] [Related]
17. Effect of interferon therapy on the incidence of hepatocellular carcinoma and mortality of patients with chronic hepatitis C: a retrospective cohort study of 738 patients.
Tanaka H; Tsukuma H; Kasahara A; Hayashi N; Yoshihara H; Masuzawa M; Kanda T; Kashiwagi T; Inoue A; Kato M; Oshima A; Kinoshita Y; Kamada T
Int J Cancer; 2000 Sep; 87(5):741-9. PubMed ID: 10925370
[TBL] [Abstract][Full Text] [Related]
18. Estimating the impact of early hepatitis C virus clearance on hepatocellular carcinoma risk.
Darvishian M; Janjua NZ; Chong M; Cook D; Samji H; Butt ZA; Yu A; Alvarez M; Yoshida E; Ramji A; Wong J; Woods R; Tyndall M; Krajden M
J Viral Hepat; 2018 Dec; 25(12):1481-1492. PubMed ID: 30047609
[TBL] [Abstract][Full Text] [Related]
19. Trends in Mortality From Extrahepatic Complications in Patients With Chronic Liver Disease, From 2007 Through 2017.
Kim D; Adejumo AC; Yoo ER; Iqbal U; Li AA; Pham EA; Cholankeril G; Glenn JS; Ahmed A
Gastroenterology; 2019 Oct; 157(4):1055-1066.e11. PubMed ID: 31251928
[TBL] [Abstract][Full Text] [Related]
20. Risk of
Antwi SO; Van Houten HK; Sangaralingham LR; Patel T
Cancer Prev Res (Phila); 2019 Dec; 12(12):891-902. PubMed ID: 31451519
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
